ClinicalTrials.gg
CompletedNCT04328480COLCOVIDUpdated Apr 27, 2021

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

A Phase 3 interventional study of Colchicine and Local standard of care in COVID-19, sponsored by Estudios Clínicos Latino América. Completed at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-27.

Sponsored by Estudios Clínicos Latino América · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,279
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in COVID-19 with a site in Argentina — 6 open to participants now, 7 under way, 5 of them phase 3. COVID-19 · Argentina.

Enrollment
29th of 87
1,279 · median 414
Started
2020
with 69 others
Phase 3
35 of 127
4 open now
Registered
2nd of 127
by date

Among the 127 studies in COVID-19 with a site in Argentina, this one is the 29th largest by enrollment of the 87 interventional ones that give a count, is one of 70 that started in 2020, is one of 35 in phase 3, and was the 2nd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 127 studies in COVID-19 with a site in Argentina are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in COVID-19 with a site in Argentina, or all of them as a file.
02

Study summary

The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement for mechanical ventilation.

Read the detailed description

Various anti-viral treatments are being tested in clinical trials worldwide. The World Health Organization (WHO) launched a simple,pragmatic worldwide open-label trial to test Remdesivir, Lopinavir/Ritonavir, Interferon and Hydroxychloroquine or Chloroquine.The most important complication of COVID-19 severe cases is respiratory failure from severe acute respiratory syndrome (SARS), the leading cause of mortality. Accumulating evidence suggests that patients with severe COVID-19 might have a cytokine storm syndrome, a hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinemia and multiorgan failure.

The proposed pathophysiological mechanism of cytokine storm and inflammatory cascade activation is based on evidence collected primarily during the SARS-CoV and MERS-CoV epidemics (with a significant increase in IL1B, IL6, IL12, IFNγ, IP10, TNFα, IL15, and IL17 among others). The data collected during the pandemic with COVID-19 also shows a significant increase in inflammatory cytokines (GCSF, IP10, MCP1, MIP1A, and TNFα, among others) in sicker patients admitted to intensive care. In the absence of effective treatments for the management of patients with COVID-19 and respiratory failure, the immunomodulatory and anti-inflammatory effect of colchicine on cytokines involved in the hyper-inflammatory state is postulated. Several lines of research worldwide are testing powerful anti-inflammatory drugs for the pandemic, with different options including steroids, cytokine blockers, and other potent anti-inflammatory agents. Steroids are partially contraindicated in viral infections.

Colchicine is a powerful anti-inflammatory drug approved for the treatment or prevention of gout and Familial Mediterranean Fever at doses ranging between 0.3 mg and 2.4 mg/day. Its mechanism of action is through the inhibition of tubulin polymerization, as well as through potential effects on cellular adhesion molecules and inflammatory chemokines. It might also have direct anti-inflammatory effects by inhibiting key inflammatory signalling networks known as inflammasome and pro-inflammatory cytokines. Additionally, evidence suggests that colchicine exerts a direct anti-inflammatory effect by inhibiting the synthesis of tumor necrosis factor alpha and IL-6, monocyte migration, and the secretion of matrix metalloproteinase-9. Through the disruption of the cytoskeleton, colchicine is believed to suppress secretion of cytokines and chemokines as well as in vitro platelet aggregation. All these are potentially beneficial effects that might diminish or ameliorate the COVID-19 inflammatory storm associated with severe forms of the disease. Importantly, in one contemporary trial low-dose colchicine administered to patients who survived from acute coronary syndrome shows a statistically significantly reduction of cardiovascular complications.

We have therefore designed in a simple, pragmatic randomized controlled trial to test the effects of colchicine on severe hospitalized COVID-19 cases with the aim of reducing mortality.

Sample size calculation:

A minimum sample size of 1200 patients will provide 80% power to detect a relative risk reduction of approximately 30% in the treated group if the assumed composite rate (new requirement of intubation and / or death) in the control group is about 24%.

The ECLA PHRI COLCOVID Trial allows randomization to another trial, specifically patients included in the trial might be (or not) randomized to an antithrombotic strategy.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consented adults (age ≥18 years) and
  • COVID-19 suspicious and
  • Admitted to hospital or already in hospital and
  • COVID-19 suggestive symptoms (fever or febrile equivalent, loss of smell and taste, fatigue, etc.) that may be present or absent at randomization time and
  • SARS (severe acute respiratory syndrome)

    • shortness of breath (dyspnea) or
    • image of typical or atypical pneumonia or
    • oxygen desaturation (SpO2 ≤ 93)

Exclusion criteria

Exclusion criteria

  • Clear indication or for the use of colchicine
  • Pregnant or breastfeeding female.
  • Chronic renal disease with \<15 ml/min/m2
  • Negative PCR test for SARS-COV2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,279 participants (actual)

Study arms

  • Active comparator
    Local standard of care plus colchicine

    Local standard of care plus colchicine (specific dosage schedule)

    Drug: Colchicine · Other: Local standard of care

  • Other
    Local standard of care

    Local standard of care for COVID-19 SARS moderate / high-risk patients

    Other: Local standard of care

Interventions

  • The colchicine dosage schedule will vary according to the following scenarios: 1. In patients not receiving Lopinavir/Ritonavir * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1) * The next day 0.5 mg bid for 14 days or until discharge. 2. In patients receiving Lopinavir/Ritonavir * Loading dose of 0.5 mg (day 1) * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge. 3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir. * Continue with 0.5 mg every 72 hours for 14 days or until discharge. Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.

    Also known as: Colchicina

  • OtherLocal standard of care

    Local standard of care for COVID-19 SARS moderate /high-risk patients

06

What researchers measure

Primary outcomes

  1. Composite outcome: New requirement for mechanical ventilation or death

    Number of participants who require new intubation for mechanical ventilation or die

    Time frame: 28 days post randomization

  2. Mortality

    Number of participants who die

    Time frame: 28 days post randomization

Secondary outcomes

  1. New requirement for mechanical ventilation or death from respiratory failure

    Number of participants who require new intubation for mechanical ventilation or die from respiratory failure

    Time frame: 28 days post randomization

  2. New requirement for mechanical ventilation or death from non-respiratory failure

    Number of participants who require new intubation for mechanical ventilation or die from non-respiratory failure

    Time frame: 28 days post randomization

  3. Mortality due to respiratory failure

    Number of participants who die from respiratory failure

    Time frame: 28 days post randomization

  4. Mortality due to non-respiratory failure

    Number of participants who die from non-respiratory failure

    Time frame: 28 days post randomization

  5. In hospital - Composite outcome

    Number of participants who require intubation for mechanical ventilation or die

    Time frame: During hospitalization or until death, whichever comes first, assessed up to 28 days

  6. In hospital - Mortality

    Number of participants who die

    Time frame: During hospitalization or until death, whichever comes first, assessed up to 28 days

  7. Composite outcome (New requirement for mechanical ventilation or death) evaluated in Non-intubated population

    Number of participants who were not intubated at randomization and require new intubation for mechanical ventilation or die

    Time frame: 28 days post randomization

  8. Mortality evaluated in Non-intubated population

    Number of participants who were not intubated at randomization and die

    Time frame: 28 days post randomization

  9. Mean WHO descriptive score of COVID-19 during hospitalization

    Mean WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group

    Time frame: During hospitalization or until death, whichever comes first, assessed up to 28 days

  10. Highest WHO descriptive score of COVID-19 during hospitalization

    Mean highest WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group

    Time frame: During hospitalization or until death, whichever comes first, assessed up to 28 days

07

Study locations

1 site
  • Sanatorio Parque
    Rosario, Santa Fe 2000, Argentina
08

References and documents

Publications

  • Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i4-i11. doi: 10.1093/rheumatology/kex453. PubMed 29272515 ↗
  • Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16. PubMed 31733140 ↗
  • Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984 Oct-Dec;3(4):409-22. doi: 10.1002/sim.4780030421. No abstract available. PubMed 6528136 ↗
  • McDermott MM, Newman AB. Preserving Clinical Trial Integrity During the Coronavirus Pandemic. JAMA. 2020 Jun 2;323(21):2135-2136. doi: 10.1001/jama.2020.4689. No abstract available. PubMed 32211830 ↗
  • Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16. No abstract available. PubMed 32192578 ↗
  • Diaz R, Orlandini A, Castellana N, Caccavo A, Corral P, Corral G, Chacon C, Lamelas P, Botto F, Diaz ML, Dominguez JM, Pascual A, Rovito C, Galatte A, Scarafia F, Sued O, Gutierrez O, Jolly SS, Miro JM, Eikelboom J, Loeb M, Maggioni AP, Bhatt DL, Yusuf S; ECLA PHRI COLCOVID Trial Investigators. Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA Netw Open. 2021 Dec 1;4(12):e2141328. doi: 10.1001/jamanetworkopen.2021.41328. Erratum In: JAMA Netw Open. 2022 Feb 1;5(2):e223150. doi: 10.1001/jamanetworkopen.2022.3150. PubMed 34964849 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Apr 2021, 12 months.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 12 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2020
First posted
Mar 31, 2020
StartActual
Apr 17, 2020
Primary completionActual
Apr 25, 2021
CompletionActual
Apr 26, 2021
Last update
Apr 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04328480
Lead sponsor
Estudios Clínicos Latino América
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Apr 17, 2020
Primary completion
Apr 25, 2021
Completion
Apr 26, 2021
Last update
Apr 27, 2021

Study contacts

Rafael Diaz, MD
principal investigator · ECLA- ICR

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion